At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02315 BIOCYTOGEN-B
Not Yet Opened 08-10 16:08:05
68.650
+6.850
+11.08%
High70.000
Low61.900
Vol5.64M
Open61.900
D1 Closing61.800
Amplitude13.11%
Mkt Cap30.69B
Tradable Cap7.62B
Total Shares447.00M
T/O375.86M
T/O Rate5.08%
Tradable Shares111.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜BIOCYTOGEN-B Rises 5.1% in Regular Trading, H1 Net Profit Expected to Surge Over 4x Amid Sustained Institutional Accumulation
Hong Kong Market Move: BIOCYTOGEN-B Surges Over 10% on Dual Antibody ADC Overseas Expansion, Preclinical CRO and Model Mouse Segments See Rising Momentum
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a China-based company primarily engaged in the provision of innovative animal models and pre-clinical pharmaceutical research and development services based on its independently developed gene-editing technology. The Company utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The Company is also engaged in the provision of gene-editing services. The Company operates its businesses in the domestic market and overseas markets.